Ascendis Pharma (ASND) Price & Analysis

Compare

669 Followers

ASND Stock Chart & Stats

$212.15

-$0.55(-0.40%)

At close: Jan 08 4:00 PM EST

$212.15

-$0.55(-0.40%)

Day’s Range― - ―

52-Week Range$118.03 - $223.19

Previous CloseN/A

Volume129.18K

Average Volume (3M)504.34K

Market Cap

$13.23B

Enterprise Value$12.40B

Total Cash (Recent Filing)$539.09M

Total Debt (Recent Filing)$813.65M

Price to Earnings (P/E)―

Beta0.69

Next Earnings

Feb 12, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.16

Shares Outstanding61,151,463

10 Day Avg. Volume690,002

30 Day Avg. Volume504,340

Financial Highlights & Ratios

PEG Ratio0.86

Price to Book (P/B)-72.81

Price to Sales (P/S)21.17

P/FCF Ratio-25.02

Enterprise Value/Market Cap0.94

Enterprise Value/Revenue19.18

Enterprise Value/Gross Profit22.10

Enterprise Value/Ebitda-93.13

Forecast

1Y Price Target

$260.15

Price Target Upside22.63% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-3.67

Revenue Forecast (FY)$810.66M

Bulls Say, Bears Say

Bulls Say

Financial PerformanceASND ended the quarter with a strong cash position and reported an operating profit as well as positive cash flow.

Product EfficacyThe combination therapy in the COACH study demonstrated a significant increase in annualized growth velocity, outperforming TransCon CNP treatment alone.

Regulatory ApprovalCompletion of the late-cycle meeting with the FDA for TransCon CNP without requests for additional information suggests a likely approval.

Bears Say

Inventory ChallengesYorvipath's performance was affected by inventory destocking and currency headwinds.

Market Expansion NeedsSkytrofa's quarterly sales have stabilized around €50mn, suggesting expansion into other indications is needed for further growth.

Report ObjectivityInvestors should be aware of potential conflicts of interest in the report that could affect its objectivity.

Ascendis Pharma News

FDA Calendar: These Are the Upcoming FDA Drug Approvals

By the end of this month, two pharmaceutical firms are set to receive a decision on their drug...

14h ago

ASND

KURA

Ascendis Pharma initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Ascendis Pharma (ASND) with an Outperform rating and $255 price target Yorvipath is...

3d ago

ASND

Ascendis Pharma publishes results from ApproaCH Trial in JAMA Pediatrics

Ascendis Pharma (ASND) announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational...

3d ago

ASND

Closing Bell Movers: Cisco jumps 7% to record highs after beat-and-raise

In the opening hour of the evening session, U.S. equity futures are slipping, with investors seemingly reluctant to...

8d ago

DLO

Ascendis Pharma reports Q3 EPS (EUR 1.00) vs. (EUR 0.72) last year

Reports Q3 revenue EUR 213.63M vs. EUR 57.83M last year. “With our achievements in the third quarter and...

8d ago

ASND

Ascendis Pharma announces new pooled analysis on TransCon PTH

Ascendis Pharma (ASND) announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function...

14d ago

ASND

Buy Rating for Ascendis Pharma Driven by Promising TransCon CNP Developments in Achondroplasia Treatment

Ascendis Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from...

3d ago

ASND

Ascendis Pharma A/S: Strong Growth and Strategic Challenges

Ascendis Pharma A/S (($ASND)) has held its Q3 earnings call. Read on for the main highlights of the...

7d ago

ASND

Ascendis Pharma: Promising Growth and Strong Market Penetration Justify Buy Rating

Analyst Yun Zhong from Wedbush maintained a Buy rating on Ascendis Pharma and increased the price target to...

8d ago

ASND

Strong Demand and Strategic Developments Drive Buy Rating for Ascendis Pharma

Analyst Tazeen Ahmad of Bank of America Securities reiterated a Buy rating on Ascendis Pharma, retaining the price...

8d ago

ASND

Ascendis Pharma Reports Strong Q3 2025 Performance

Ascendis Pharma A/S ( ($ASND) ) has released its Q3 earnings. Here is a breakdown of the information...

8d ago

ASND

Ascendis Pharma Grants Warrants to Employees in Strategic Move

Ascendis Pharma ( ($ASND) ) has shared an update. On November 11, 2025, Ascendis Pharma’s board of directors...

8d ago

ASND

Ascendis Pharma Reports Q3 2025 Financial Results with Revenue Growth

Ascendis Pharma ( ($ASND) ) has shared an announcement. Ascendis Pharma released its unaudited condensed consolidated interim financial...

8d ago

ASND

Ascendis Pharma Achieves Strong Q3 2025 Financial Results Amid Product Expansion

An announcement from Ascendis Pharma ( ($ASND) ) is now available. Ascendis Pharma reported strong financial results for...

8d ago

ASND

ASND FAQ

What was Ascendis Pharma’s price range in the past 12 months?

Ascendis Pharma lowest stock price was $118.03 and its highest was $223.19 in the past 12 months.

What is Ascendis Pharma’s market cap?

Ascendis Pharma’s market cap is $13.23B.

When is Ascendis Pharma’s upcoming earnings report date?

Ascendis Pharma’s upcoming earnings report date is Feb 12, 2026 which is in 83 days.

How were Ascendis Pharma’s earnings last quarter?

Ascendis Pharma released its earnings results on Nov 12, 2025. The company reported -$1.159 earnings per share for the quarter, missing the consensus estimate of -$0.283 by -$0.876.

Is Ascendis Pharma overvalued?

According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ascendis Pharma pay dividends?

Ascendis Pharma does not currently pay dividends.

What is Ascendis Pharma’s EPS estimate?

Ascendis Pharma’s EPS estimate is -0.1.

How many shares outstanding does Ascendis Pharma have?

Ascendis Pharma has 61,151,463 shares outstanding.

What happened to Ascendis Pharma’s price movement after its last earnings report?

Ascendis Pharma reported an EPS of -$1.159 in its last earnings report, missing expectations of -$0.283. Following the earnings report the stock price went up 3.629%.

Which hedge fund is a major shareholder of Ascendis Pharma?

Currently, no hedge funds are holding shares in ASND

Ascendis Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

11.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ascendis Pharma

Ascendis Pharma is a biopharmaceutical company focused on innovative therapies for rare diseases and other serious conditions. The company operates primarily in the endocrinology sector and is known for its transformative product development approach, particularly its TransCon technology platform. Ascendis Pharma's core products include therapies aimed at growth hormone deficiencies and other endocrine disorders, leveraging its proprietary drug delivery methods to enhance patient outcomes.

Ascendis Pharma (ASND) Earnings & Revenues

Historic Earnings Reports

ASND Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong revenue growth and expansion in global markets for Eurvipath and Skytrofa, regulatory approvals, and a positive operating profit. However, challenges remain with the conversion rate for insurance approvals and increased SG&A expenses due to commercial expansion. Foreign currency impacts also affected revenue growth.View all ASND earnings summaries

ASND Stock 12 Month Forecast

Average Price Target

$260.15

▲(22.63% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","225":"$225","326":"$326","174.5":"$174.5","275.5":"$275.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$325.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":260.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$260.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":220,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$220.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,174.5,225,275.5,326],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,201.6,211.09230769230768,220.58461538461538,230.07692307692307,239.56923076923076,249.06153846153845,258.55384615384617,268.04615384615386,277.53846153846155,287.03076923076924,296.5230769230769,306.0153846153846,315.5076923076923,{"y":325,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,201.6,206.10384615384615,210.6076923076923,215.11153846153846,219.6153846153846,224.11923076923077,228.62307692307692,233.12692307692305,237.6307692307692,242.13461538461536,246.6384615384615,251.14230769230767,255.64615384615382,{"y":260.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,201.6,203.01538461538462,204.43076923076922,205.84615384615384,207.26153846153846,208.67692307692306,210.09230769230768,211.5076923076923,212.92307692307693,214.33846153846153,215.75384615384615,217.16923076923078,218.58461538461538,{"y":220,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":125.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >